Loading patent…
AssigneeBioverativ Therapeutics Inc.
InventorsVolker SCHELLENBERGER, Pei-Yun CHANG, Fatbardha VARFAJ, John KULMAN, Tongyao LIU, Garabet G. TOBY, Haiyan JIANG, Robert PETERS, Deping WANG, Baisong MEI, Joshua SILVERMAN, Chia-Wei WANG, Benjamin SPINK, Nathan GEETHING
Estimating the term…
The present invention relates to compositions comprising factor VIII coagulation factors linked to extended recombinant polypeptide (XTEN), isolated nucleic acids encoding the compositions and vectors and host cells containing the same, and methods of making and using such compositions in treatment of factor VIII-related diseases, disorders, and conditions.
A fusion protein comprising a factor VIII (FVIII) polypeptide fused to an extended recombinant polypeptide (XTEN), wherein the XTEN comprises one or more XTEN sequence motifs, and
A method of treating coagulopathy in a subject, comprising administering to the subject a composition comprising a therapeutically effective amount of a fusion protein comprising a FVIII polypeptide fused to an XTEN.
A method of controlling or ameliorating a bleeding episode in a subject in need thereof comprising administering to the subject a therapeutically effective amount of a fusion protein comprising a FVIII polypeptide fused to an XTEN.
Dependencies are inferred from the claim text.